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Background: The long-term prognosis following herpes simplex virus (HSV) central nervous
system (CNS) infection is still debated.
Patients and Methods: We examined outcomes in all Danish residents who, during
2000–2016, tested PCR positive for HSV-1 (n=208) or HSV-2 (n=283) in the cerebrospinal
fluid, compared to comparison cohorts from the general population (n=2080 and n=2830).
Results: One-year mortality was increased among HSV-1 patients (difference 19.3%; 95%
CI: 13.6% to 25.0%) and HSV-2 patients (difference 5.3%; 95% CI: 2.5% to 8.1%), but
thereafter mortality was not increased. After exclusion of persons diagnosed with cancer
prior to study inclusion, one-year mortality difference for HSV-2 patients was 1.7% (−0.1%
to 3.5%). After five years, HSV-1 patients had lower employment (difference −19.8%; 95%
CI: −34.7% to −4.8%) and higher disability pension rates (difference 22.2%; 95% CI: 8.4%
to 36.0%) than the comparison cohort, but similar number of inpatient days, outpatient visits,
and sick leave. HSV-2 patients had employment and disability pension rates comparable to
the comparison cohort, but more inpatient days (difference 1.5/year; 95% CI: −0.2 to 3.2),
outpatient visits (difference 1.3/year; 95% CI: 0.3 to 3.2), and sick leave days (difference 9.1/
year; 95% CI: 7.9 to 10.4).
Conclusion: HSV-1 and HSV-2 CNS infections differ substantially with respect to prog-
nosis. HSV-1 CNS infection is followed by increased short-term mortality and long-term risk
of disability. HSV-2 CNS infection has no substantial impact on mortality or working
capability but is associated with increased morbidity.
Keywords: herpes simplex virus encephalitis, herpes simplex virus meningitis, prognosis,
outcome, cohort study
Introduction
Herpes simplex viruses (HSVs) are well-known pathogens of viral central nervous
system (CNS) infections1,2 and can manifest as both meningitis and encephalitis.
HSV is the most common cause of sporadic fatal encephalitis globally,1,3 and the
majority of cases (up to 90%) are caused by HSV type 1 (HSV-1).4,5 Antiviral
therapy of HSV encephalitis has improved the prognosis,6 but mortality is still
10–20%,4 and a recent study of narrative interviews emphasized the magnitude of
challenges and socioeconomic consequences still faced by these patients years after
being treated for acute HSV encephalitis.7
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The main clinical manifestation of HSV type 2 (HSV-
2) CNS infection is meningitis.8 Some, but not all studies,
have shown an increased risk of neurological morbidity
after HSV-2 meningitis,8–10 and a recent UK-study found
that patients with HSV-2 meningitis had a lower quality of
life than healthy controls at one-year follow-up.2
Studies on long-term outcomes of HSV CNS infections
are scarce and often hampered by small or selected study
populations restricted to patients with severe HSV encepha-
litis, patients admitted to referral centers, or patients from
a single center, and by lack of adequate comparison
cohorts.5,6,10,11 Follow-up rarely exceeds one year,12 and
no studies have included complete national data on all
HSV-1 and HSV-2 CNS infections.4,13–15 Information on
the long-term prognosis following an episode of HSV CNS
infection is essential for improving of clinical decision mak-
ing and planning long-term patient management and will be
of great utility to patients and health care providers alike.16
We used a nationwide population-based cohort design
described in previous studies,17,18 to examine long-term
survival, morbidity, social functioning and risk of disabil-
ity among patients with HSV-1 and HSV-2 CNS infec-
tions, compared to age- and sex-matched comparison
cohorts drawn from the general population.
Patients and Methods
Setting
On December 31, 2016, Denmark had a population of
5.7 million. Tax-supported health care is provided free of
charge to all Danish residents.19
Data Sources
We used a nationwide population-based cohort design,
described in previous studies.17,18 The unique 10-digit
personal identification number, assigned to all Danish
residents at birth or upon immigration, was used to track
individuals in the Danish national health and administra-
tive registries. Data on positive polymerase chain reaction
(PCR) tests for HSV-1 and HSV-2 infections in the cere-
brospinal fluid (CSF) were obtained from all Danish
microbiology laboratories performing the test during the
period January 1, 2000 to March 1, 2016. Additional data
were obtained from the Danish Civil Registration System
(CRS), the Danish National Patient Registry (DNPR), the
Danish Cancer Registry, the Employment Classification
Module, the Danish Educational Attainment Registry as
well as housing statistics from Statistics Denmark (see
Supplementary Appendices 1–4).19
Study Population
HSV Patient Cohorts
The patient cohorts included Danish residents with
a positive PCR test for HSV-1 or HSV-2 in the CSF during
the period January 1, 2000–March 1, 2016. We defined the
date of the first positive HSV PCR test in the CSF as the
date of study inclusion.
Population Comparison Cohorts
For each HSV patient, we used the CRS to identify all
Danish residents who had not tested PCR-positive for
HSV-1 or HSV-2 in the CSF and with the same sex and
date of birth as the patient.20 From this population, we
extracted 10 individuals at random for each patient and
constructed a comparison cohort for the HSV-1 cohort and
a comparison cohort for the HVS-2 cohort. Individuals in
the comparison cohorts were assigned the same date of
study inclusion as the HSV-1 or HSV-2 patients to whom
they were matched.
Outcomes
Outcomes were categorized into the following categories:
(1) all-cause mortality and risk of cancer, (2) neuropsy-
chiatric sequelae (dementia and epilepsy), (3) health care
utilization as a measure of morbidity (hospitalizations,
outpatient visits, visits to a department of neurology), (4)
outcomes that might reflect impaired social functioning or
disability (unemployment, disability pension, sick leave,
nursing home residency, marriage and divorce rates), and
(5) unfavorable outcome defined as a combined endpoint
of death and measures of severe disability (receipt of
a disability pension, nursing home residency, dementia).
Statistical Analyses
We calculated time from date of study inclusion to
1 March 2016, death, emigration, loss to follow up, or
event of interest, whichever came first. Mortality rate
ratios (MRRs) and incidence rate ratios (IRRs) were cal-
culated as measures of relative risk.
For each person in the HSV-1 and HSV-2 cohorts and
their corresponding comparison cohorts, we ascertained the
yearly number of hospital inpatient days, outpatient hospital
visits, proportion visiting a neurology department, propor-
tion having a hospital contact associated with a diagnosis of
epilepsy, employment status, sick leave days, receipt of
Hansen et al Dovepress
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a disability pension, marital status, and residency in
a nursing home. Ascertainment started six years prior to
the date of study inclusion, birth, immigration, or start-up
date of the registry that recorded the outcome of interest.
Data collection continued up until the earliest of the follow-
ing events: six years after study inclusion, March 1, 2016,
death, emigration, or loss to follow-up. For each outcome,
we calculated differences between the patient and compar-
ison cohorts with 95% CIs. Analyses of sick leave, employ-
ment and receipt of a disability pension were restricted to
individuals aged 20–60 years at study inclusion. In addition,
analysis of sick leave only included individuals registered as
employed. To account for potential differences in comorbid-
ity among study participants at the time of study inclusion,
we calculated the fraction of individuals with a Charlson
Comorbidity Index (CCI) score >0 at study inclusion.21,22
We performed supplementary sensitivity analyses of mortal-
ity, time to unfavorable outcome, annual number of hospital
inpatient days and outpatient visits, in which we excluded
individuals with a diagnosis of cancer prior to the date of
study inclusion.
SPSS Statistics, version 24 (SPSS, Inc., Chicago,
Illinois) and STATA version 14 were used for analysis.
Approvals and Ethics
In Denmark, research based on registry data without direct
patient interaction does not require scientific ethical approval.
The study was approved by the Danish Data Protection
Agency and the National Board of Health (RH-2015-285,
I-Suite no.: 04297).
Results
During the study period, we identified 208 persons with
a positive PCR test for HSV-1 and 283 with a positive test
for HSV-2 in the CSF and included 2080 and 2830 persons
in the matched HSV-1 and HSV-2 comparison cohorts. The
HSV-1 group was older than the HSV-2 group (median age
60 years versus 38 years) and included fewer women (54%
versus 71%). Both HSV-1 and HSV-2 patients had slightly
higher CCI scores and prevalence of cancer prior to study
inclusion than members of the comparison cohorts (Table 1).
Mortality and Risk of Cancer
During the observation period, 69 (33%) HSV-1 patients and
21 (7%) HSV-2 patients died compared with 288 (13%) and
77 (3%) deaths in the corresponding comparison cohorts
(Table 1). Risk of death was substantially increased in the
first year after diagnosis of HSV CNS infection; MRR was
10.9 (95% CI: 7.3 to 16.4) for HSV-1 patients and 8.4 (95%
CI: 4.4 to 16.0) for HSV-2 patients. One-year absolute excess
mortality was 19.3% (95% CI: 13.6% to 25.0%) in the HSV-1
group and 5.3% (95% CI: 2.5% to 8.1%) in the HSV-2 group.
Eleven of 17 patients, who died within the first year after
diagnosis of an HSV-2 CNS infection, had been diagnosed
with cancer before the HSV-2 diagnosis. Exclusion of persons
diagnosedwith cancer before study inclusion changed the one-
year risk difference estimate only marginally for the HSV-1
group but reduced the estimate for HSV-2 patients to 1.7%
(95% CI: −0.1% to 3.5%). After one year, neither mortality
nor risk of a new cancer diagnosis were substantially increased
among HSV-1 or HSV-2 patients (Table 2, Figure 1).
Neuropsychiatric Sequelae
The risk of a dementia diagnosis was increased in the HSV-
1 cohort the first years after HSV-1 CNS infection with
a five-year risk of 4.6% (95% CI: 1.2% to 7.9%) corre-
sponding to a five-year risk difference of 4.0% (95% CI:
0.6% to 7.4%) (Supp. Figure 1). In contrast, no individuals
in the HSV-2 cohort were diagnosed with dementia. HSV-1
patients had more hospital contacts with a diagnosis of
epilepsy from the year of their HSV-1 CNS infection and
throughout follow up. Five years after study inclusion, the
risk difference was 7.5% (95% CI: 1.9% to 13.1%). During
the year of diagnosis, HSV-2 patients had more hospital
contacts associated with a diagnosis of epilepsy than mem-
bers of the comparison cohort but thereafter the risk waned
and approached that observed in the comparison cohort
(Table 3, Supp. Figure 2).
Health Care Utilization
During the year of HSV diagnosis, days of hospitalization
and outpatient visits were considerably higher in both
patient cohorts than in the comparison cohorts. Thereafter,
use of hospital services decreased but remained somewhat
higher in the HSV-2 cohort than in the comparison cohort
(Table 3, Supp. Figure 3). Of note, HSV-2 patients also had
more days of hospitalization and more outpatient visits in
the years prior to diagnosis. In a sensitivity analysis exclud-
ing individuals with a cancer diagnosis prior to study inclu-
sion, HSV-2 patients still showed increased use of hospital
services before as well as after HSV-2 diagnosis.
After diagnosis of an HSV CNS infection, the propor-
tion visiting a neurology department annually was
increased among both HSV-1 and HSV-2 patients. After
five years, the risk differences were 18.3% (95% CI: 9.9%
Dovepress Hansen et al
Clinical Epidemiology 2020:12 submit your manuscript | www.dovepress.com
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to 26.7%) for HSV-1 patients and 5.5% (95% CI: 1.2% to
9.8%) for HSV-2 patients (Table 3, Supp. Figure 4).
Unemployment, Sick Leave and Receipt of
Disability Pension, Nursing Home
Residency, Marriage and Divorce Rates
The employment rate for the HSV-1 cohort was slightly
lower than in the comparison cohort prior to diagnosis of
HSV-1 CNS infection, but thereafter the employment rates
decreased substantially. In contrast, the HSV-2 cohort did
not have decreased employment rates before or after diag-
nosis (Table 3, Supp. Figure 5).
Among HSV-1 patients, the number of sick leave days
was higher than for members of the comparison cohort
during the year of diagnosis and the year thereafter, but
two years after diagnosis the number of sick leave days
was similar to that in the comparison cohort (Table 3,
Supp. Figure 5). The number of sick leave days in the
HSV-2 cohort was higher than for the comparison cohort
in the year of study inclusion and throughout follow-up.
Before study inclusion, the proportion on disability
pensions was slightly higher in the HSV-1 cohort than in
the comparison cohort. After the HSV-1 diagnosis, the
proportion on disability pension increased considerably.
In contrast, the proportion on disability pension did not
differ greatly between the HSV-2 cohort and the compar-
ison cohort (Table 3, Figure 2).
More patients resided at a nursing home after diagnosis
of HSV CNS infections than members of the comparison
cohorts. One-year risk differences were 17.3% (95% CI:
11.8% to 22.8%) for HSV-1 patients and 1.8% (95% CI:
0.0% to 3.6%) for HSV-2 patients.
The proportion of HSV-1 patients who were married was
almost identical to that observed in the comparison cohort,
while the HSV-2 patients were less likely to be married than
the comparison cohort (Table 3, Supp. Figure 6). The propor-
tion of HSV-1 patients who were divorced seemed to increase
slightly after diagnosis of their HSV CNS infection. In con-
trast, the proportion of divorce in the HSV-2 cohort was higher
than in the comparison cohort before as well as after diagnosis
of their HSV-2 CNS infection (Table 3, Supp. Figure 6).
Unfavorable Outcome
To examine the overall risk of an unfavorable outcome, we
computed time to an adverse outcome defined as the
Table 1 Characteristics of Patients with HSV-1 and HSV-2 in Cerebrospinal Fluid, and Their Corresponding Comparison Cohorts,
Denmark, 2000–2016
Characteristics HSV-1
Cohort
Population Comparison
Cohort HSV-1
HSV-2
Cohort
Population Comparison
Cohort HSV-2
Total 208 2080 283 2830
Female sex – no. (%) 112 (54) 1120 (54) 201 (71) 2010 (71)
Median age at study inclusion – years
(interquartile range)
60 (41–70) 60 (41–70) 38 (28–48) 38 (28–48)
Age below 16 years at study inclusion (%) 16 (8) 160 (8) 7 (2) 70 (2)
Age between 20–60 years at study inclusion
(%)
90 (43) 900 (43) 247 (87) 2470 (87)
Born in Denmark – no. (%) 197 (95) 1922 (92) 266 (94) 2486 (88)
High school education (%) 111 (53) 1116 (54) 188 (66) 1893 (67)
Charlson Comorbidity Index score >0 – no.
(%)¶,$
73 (35) 547 (26) 57 (20) 366 (13)
Cancer, total – no. (%)$ 29 (14) 192 (9) 21 (7) 108 (4)
Median observation time – years
(interquartile range)
3.7
(0.7–9.1)
6.2 (2.5–10.1) 5.2
(2.2–9.9)
5.5 (2.7–10.5)
Total observation time, years 1071 13,431 1671 18,114
Died – no. (%)# 69 (33) 288 (14) 21 (7) 77 (3)
Diagnosed with cancer – no. (%)# 12 (6) 161 (8) 7 (2) 83 (3)
Diagnosed with dementia – no. (%)# 7 (3) 21 (1) 0 (0) 7 (0)
Emigrated – no. (%)# 3 (1) 26 (1) 11 (4) 43 (2)
Lost to follow up – no. (%)# 0 (0) 1 (0) 0 (0) 5 (1)
Notes: ¶The Charlson Comorbidity Index (CCI) score derived from diagnoses recorded in the Danish National Patient Registry at study inclusion. For simplicity, we
dichotomized scores (CCI score=0 and CCI score >0). $Diagnosed before study inclusion, #After study inclusion.
Abbreviations: HSV-1, herpes simplex virus type 1; HSV-2, herpes simplex virus type 2.
Hansen et al Dovepress
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composite endpoint of death, receipt of disability pension,
dementia diagnosis, or nursing home residency. The five-year
risk of an unfavorable outcome was 48% (95% CI: 40% to
55%) in the HSV-1 cohort, corresponding to a risk difference
of 36% (95% CI: 28% to 44%) relative to the comparison
cohort. HSV-2 patients had an increased five-year risk of an
Table 2 Mortality Rate Ratios (MRRs) and Incidence Rate Ratios (IRRs) for Cancer and Dementia Diagnoses in Patients with HSV-1
and HSV-2 in Cerebrospinal Fluid Compared with Members of the Matched Comparison Cohorts
HSV-1 Patients versus Comparison
Cohort Members
HSV-2 Patients versus Comparison
Cohort Members
Mortality MRR 95% CI MRR 95% CI
Mortality in first year of follow-up 10.9 7.3, 16.4 8.4 4.4, 16.0
Mortality from the second year and onwards 1.3 0.8, 1.9 0.8 0.3, 2.2
Morbidity IRR 95% CI IRR 95% CI
Cancer 0.9 0.5, 1.7 0.9 0.4, 2.0
Abbreviations: HSV-1, herpes simplex virus type 1; HSV-2, herpes simplex virus type 2; CI, confidence interval.
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Figure 1 Survival in persons with herpes simplex virus (HSV) type 1 and type 2 central nervous system (CNS) infection (full lines) and in members of the comparison cohorts
(broken lines). (A) Survival after HSV-1 CNS infection. (B) Survival after HSV-2CNS infection. (C) Survival after HSV-2CNS infection in persons without a prior diagnosis of cancer.
Dovepress Hansen et al
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Table 3 Hospitalization Inpatient Days, Number of Outpatient Visits, Proportion Visiting a Department of Neurology, Proportion
with a Hospital Visit Associated with Epilepsy, Employment Status, Sick Leave, Proportion Receiving Disability Pension, and Marital
Status Among Patients with HSV-1 or HSV-2 in Cerebrospinal Fluid and Members of the Comparison Cohorts
Years from
Study
Inclusion
Patients
with HSV-
1
Comparison
Cohort
Difference 95% CI of
Difference
Patients
with HSV-
2
Comparison
Cohort
Difference 95% CI of
Difference
Hospitalization (mean inpatient days/year)
−2 1.5 1.0 0.5 −0.6, 1.6 1.3 0.5 0.9 −0.3, 2.0
0 55.6 1.6 54.1 47.3, 60.9 16.2 0.8 15.4 11.9, 19.0
1 2.5 1.5 1.1 −0.3, 2.5 1.5 0.7 0.8 0.1, 1.5
2 3.2 1.3 1.9 0.1, 3.6 1.6 0.6 1.0 −0.1, 2.1
5 1.7 1.4 0.3 −1.5, 2.0 2.1 0.6 1.5 −0.2, 3.2
Outpatient visits (mean visits/year)
−2 2.5 1.8 0.6 −0.3, 1.5 2.5 1.4 1.2 −0.1, 2.4
0 11.7 2.1 9.6 4.2, 14.9 5.0 1.5 3.5 2.4, 4.6
1 3.2 2.2 1.0 −0.1, 2.1 3.0 1.7 1.4 0.1, 2.6
2 2.1 2.4 −0.3 −1.2, 0.5 3.2 1.7 1.5 −0.2, 3.2
5 2.3 2.4 −0.1 −1.1, 0.8 3.2 1.9 1.3 0.3, 3.2
Proportion visiting a department of neurology (%)
−2 3.0 2.3 0.7 −1.7, 3.1 1.8 1.5 0.3 −1.4, 1.9
0 33.2 1.9 31.3 24.9, 37.7 15.2 2.1 13.1 8.9, 17.3
1 34.8 2.0 32.8 25.3, 40.4 10.3 2.2 8.1 4.3, 11.9
2 23.6 2.3 21.3 14.2, 28.4 6.3 2.1 4.2 1.1, 7.4
5 20.2 2.0 18.3 9.9, 26.6 7.5 2.2 5.5 1.2, 9.8
Proportion with a hospital visit associated with a diagnosis of epilepsy
−2 0.5 0.2 0.2 −0.7,1.2 0.0 0.3 −0.3 −0.5, −0.1
0 17.8 0.1 17.6 12.4, 22.8 2.8 0.2 2.6 0.7, 4.6
1 17.4 0.1 17.3 11.3, 23.3 0.8 0.3 0.5 −0.7, 1.6
2 10.0 0.2 9.8 4.8, 14.7 0.9 0.3 0.6 −0.6, 1.9
5 7.9 0.3 7.5 1.9, 13.1 0.7 0.1 0.6 −0.8, 1.9
Proportion employed (%)#
−2 77.0 85.1 −8.0 −17.2, 1.1 85.9 82.3 3.6 −1.1, 8.3
0 72.5 82.4 −9.9 −20.0, 0.3 78.7 79.7 −1.0 −6.8, 4.9
1 54.4 74.9 −20.5 −32.7, −8.2 79.3 80.7 −1.4 −7.6, 4.9
2 59.4 77.0 −17.6 −30.0, −5.2 75.8 77.5 −1.8 −8.8, 5.2
5 52.2 72.0 −19.8 −34.7, −4.8 80.6 77.0 3.6 −4.6, 11.9
Days of sick leave/year$
−2 10.6 17.5 −6.9 −7.7, −6.0 23.5 23.0 0.5 −0.2, 1.2
0 134.4 20.2 114.2 111.0, 117.4 49.9 24.3 25.7 24.5, 26.8
1 97.1 14.9 82.2 78.9, 85.4 39.3 24.5 14.8 13.7, 15.9
2 25.0 14.2 10.9 9.1, 12.6 21.7 24.4 −2.7 −3.6, −1.8
5 6.9 11.2 −4.3 −5.5, −3.1 28.6 19.5 9.1 7.9, 10.4
Proportion on disability pension (%)#
−2 12.6 7.6 5.1 −2.1, 12.3 5.1 3.7 1.4 −1.5, 4.3
0 15.0 9.3 5.8 −2.3, 13.8 6.8 4.6 2.2 −1.4, 5.7
1 19.1 10.4 8.7 −0.9, 18.3 6.3 5.0 1.3 −2.5, 5.0
(Continued)
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unfavorable outcome [risk difference 5% (95% CI: 1% to
9%)], relative to the comparison cohort (Figure 3). The risk
in HSV-2 patients was driven mainly by increased mortality
during the first year after diagnosis, and after exclusion of
persons diagnosed with cancer prior to study inclusion, the
risk difference was reduced to 2% (95% CI: −2% to 5%).
Discussion
In this nationwide population-based cohort study, we
examined long-term outcomes following HSV-1 and
HSV-2 CNS infections. During the first year following
a diagnosis of HSV-1 CNS infection, the mortality was
high with a fatal outcome in one-fifth of patients, and after
five years nearly half of the patients had died or experi-
enced severe disability. HSV-2 patients also had increased
mortality in the first year following diagnosis of CNS-
infection, but this was mainly explained by the higher
proportion of patients diagnosed with cancer before study
inclusion, and HSV-2 patients did not have increased long-
term risk of severe outcomes.
The study’s nationwide population-based design, large
size, and the complete and long-term follow-up of the study
cohorts allowed more precise risk estimates and a better
understanding of long-term outcomes in the years following
discharge from the acute hospital setting. Access to national
registries allowed identification of well-matched population-
based comparison cohorts, and these registries provided
complete data on date of death and comprehensive data on
morbidity, neurological sequelae, and social functioning. We
included cases based on detection of HSV DNA in the CSF.
PCR detection of HSV in the CSF has a sensitivity and
specificity above 95%23 and we consider it a strength that
all cases were microbiologically confirmed. We did not use
the diagnoses of meningitis or encephalitis in our analyses, as
the accuracy of these diagnoses in the DNPR is low.24
However, HSV-1 CNS infection presents almost exclusively
as encephalitis,3 while HSV-2 CNS infection presents mainly
as meningitis,10 although up to 10–15% of patients with
HSV-2 CNS infections do present as encephalitis or
meningoencephalitis.5,8 We did not have access to clinical
information such as neuropsychological evaluations or func-
tional motor assessments in patients with an HSV CNS
infection, but we were able to evaluate the level of social
functioning regarding important aspects of life such as work-
ing capability, marital status and nursing home residence and
to compare this functional status with that in the general
population using prospectively collected registry data. We
started ascertainment six years prior to the diagnosis of HSV
Table 3 (Continued).
Years from
Study
Inclusion
Patients
with HSV-
1
Comparison
Cohort
Difference 95% CI of
Difference
Patients
with HSV-
2
Comparison
Cohort
Difference 95% CI of
Difference
2 28.1 11.4 16.7 5.4, 28.0 9.6 6.0 3.6 −1.2, 8.3
5 32.6 10.4 22.2 8.4, 36.0 7.1 8.3 −1.1 −6.5, 4.2
Proportion married (%)*
−2 73.0 70.1 2.9 −3.7, 9.6 41.1 47.2 −6.2 −12.4, 0.1
0 73.0 70.7 2.3 −4.3, 9.0 42.3 50.7 −8.4 −14.6, −2.1
1 75.2 70.3 4.9 −2.6, 12.3 38.9 53.1 −14.2 −20.7, −7.7
2 75.0 70.5 4.5 −3.3, 12.3 38.9 54.4 −15.5 −22,4, −8.6
5 69.2 70.7 −1.4 −12.0, 9.2 42.6 57.7 −15.2 −23.7, −6.7
Proportion divorced (%)*
−2 7.9 11.4 −3.4 −7.6, 0.7 14.1 8.0 6.1 1.7, 10.4
0 9.5 11.9 −2.3 −6.8, 2.1 16.1 8.7 7.4 2.8, 11.9
1 10.6 12.6 −1.9 −7.2, 3.4 19.2 9.3 10.0 4.8, 15.1
2 12.5 13.3 −0.8 −6.8, 5.2 19.0 9.4 9.6 4.1. 15.0
5 14.1 13.6 0.5 −7.5, 8.5 23.4 11.2 12.2 5.0, 19.4
Notes: #Includes only individuals aged 20–60 years at study inclusion. *Includes only individuals aged >20 years at study inclusion. $Includes only individuals aged 20–60 years
at study inclusion and registered as employed.
Abbreviations: HSV-1, herpes simplex virus type 1; HSV-2, herpes simplex virus type 2; CI, confidence interval.
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CNS infection; thus, we were able to determine whether
differences in outcomes between patient and population con-
trol cohorts were present prior to the diagnosis of HSV CNS
infection.
We found very high one-year mortality following an
episode of HSV-1 CNS infection with excess absolute mor-
tality of 19%. This finding is consistent with a previous
Danish report of mortality among patients with HSV
encephalitis,4 but higher than estimates presented in other
population-based European studies, in which one-year mor-
tality ranged from 10% to 14%.12–14 Importantly, our study
provides new information about the serious long-term con-
sequences of the diseases. After five years of follow-up,
almost half of the HSV-1 group (47%) had experienced either
death or an unfavorable outcome. Further, the unemployment
rate increased after the diagnosis of HSV-1 CNS infection,
suggesting that working capability may also be affected
among some patients who did not experience an unfavorable
outcome. Some short-term studies have found neurological
sequelae or disability in approximately 40–50% of the
patients with HSV encephalitis.5,6,14 Our study provides
further documentation that the sequelae seem to translate
into long-term disability.
A nationwide Swedish register-based study reported
considerable morbidity after HSV encephalitis, including
hospital readmission for epilepsy and neuropsychiatric
conditions in 24% and 22% of survivors, respectively.12
We found that a large proportion of HSV-1 patients had
long-term neurological sequelae, including epilepsy. Five
years after diagnosis one-fifth of patients still had at least
one annual visit to a neurology department and 7.5% had
a hospital visit associated with epilepsy. Despite the
increased neurological morbidity, overall rates of use of
hospital services approached the rates seen in the compar-
ison cohort following the first year of diagnosis. The
annual number of sick leave days returned to the same
level as in the comparison cohort after two years. Of note,
many patients had stopped their professional work which
may partly explain the return to average levels of sick
leave days in the remaining patients capable of returning
to work after their episode of HSV-1 CNS infection.
While HSV-2 CNS infectionmay be associatedwith recur-
rent meningitis and short-term neurological morbidity,8,9 our
study corroborates the benign long-term prognosis of HSV-2
CNS infection,with little risk ofmajor disability. The increased
risk of death observed during the first year of follow-up was
mainly attributable to an increased proportion of patients diag-
nosed with cancer before diagnosis of HSV-2 CNS infection.
HSV-2 is more likely to be reactivated in immunocompro-
mised patients, including patients receiving chemotherapy for
malignant disorders and especially in patients receiving
treatment for hematological malignancies.25 Further, immuno-
compromised patients have more serious HSV-2
manifestations.26,27 These factors may explain the increased
proportion with a cancer diagnosis prior to study inclusion in
the HSV-2 cohort. In a previous Danish study of 49 patients
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Figure 2 Proportion on disability pension* among patients with herpes simplex virus (HSV) type 1 and type 2 central nervous system infections (black) and members of the
comparison cohorts (white) by years before and after study inclusion. (A) HSV-1 CNS infection. (B) HSV-2 CNS infection.
Note: *Among individuals aged 20–60 years at study inclusion.
Hansen et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Clinical Epidemiology 2020:12752
 
C
lin
ic
al
 E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
87
.5
3.
13
1.
89
 o
n 
12
-A
ug
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
with HSV-2 CNS infection, there were no deaths resulting
from CNS disease, but one patient died from malignant
lymphoma.8
The HSV-2 patients in the current study had slightly
increased use of hospital inpatient and outpatient services
both before and after study inclusion. Our data does not
allow us to explain this finding, but it is possible that
symptoms from primary and recurrent genital HSV-228–30
lead to increased use of hospital services. In two other series
of patients with HSV-2 CNS infection, 20% and 45% had
more than one episode of meningitis, which also may have
increased the use of health care services.8,10 Further, in our
study HSV-2 patients had higher levels of comorbidity than
the comparison cohort. Five years after diagnosis of the
HSV-2 CNS infection, the proportion of patients with at
least one annual visit to a neurology department also
remained around five percentage points higher than in the
comparison cohort. However, the measures of increased
morbidity did not translate into increased rates of unemploy-
ment or receipt of disability pensions. In contrast to HSV-1
patients, the risk of epilepsy was not persistently increased
in the HSV-2 group except during the first year after diag-
nosis. It remains possible that some patients with convul-
sions, during the acute phase of HSV CNS infection, may
have been misdiagnosed with epilepsy. Our results are in
line with the results of a smaller single-center study, which
found no neurological disability or death among 28 patients
with HSV-2 meningitis during median follow-up time of 3.4
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Figure 3 Cumulative incidence of an unfavorable outcome (death, dementia, receipt of a disability pension, and nursing home residency) in patients with herpes simplex
virus (HSV) type 1 and type 2 central nervous system (CNS) infections (full lines) and members of the comparison cohorts (broken lines). (A) Unfavorable outcome after
HSV-1 CNS infection. (B) Unfavorable outcome after HSV-2 CNS infection. (C) Unfavorable outcome after HSV-2 CNS infection in persons without a prior diagnosis of
cancer.
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years.10 In our study, the proportion divorced in the HSV-2
group was higher than in the comparison cohort before, as
well as after, HSV-2 diagnosis. This may partly reflect that
HSV-2 is a sexually transmitted disease associated with
partner changes or greater numbers of sexual partners.31
Conclusions
In summary, our study demonstrates that HSV-1 and HSV-2
CNS infections have distinct long-term prognoses. HSV-1
CNS infection has high one-year mortality and survivors are
at considerable risk of neurological sequelae and long-term
disability. In contrast, HSV-2 CNS infection has no substantial
impact on mortality or long-term risk of serious neurological
sequelae and disability, although a diagnosis of HSV-2 CNS
infection is associated with some measures of increased
morbidity.
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